Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant chemotherapy, which caused a high rate of severe toxicity, according to a large randomized trial.
Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant chemotherapy, which caused a high rate of severe toxicity, according to a large randomized trial.